A device that is at least partially formed of a biodegradable polymer. The device can be at least partially formed by MEMS technology. The device can include one or more micro-structures that are also formed by MEMS technology. The device can include one or more agents that can be controllably and/o
A device that is at least partially formed of a biodegradable polymer. The device can be at least partially formed by MEMS technology. The device can include one or more micro-structures that are also formed by MEMS technology. The device can include one or more agents that can be controllably and/or uncontrollably released from the device.
대표청구항▼
1. An expandable medical device for insertion in a body passageway that is used in treating dissected blood vessels, vascular malformations, vulnerable plaque by encapsulation, vulnerable plaque by passivation, nerve dissection of the central nervous system, incompetent valves, pulmonary embolism, n
1. An expandable medical device for insertion in a body passageway that is used in treating dissected blood vessels, vascular malformations, vulnerable plaque by encapsulation, vulnerable plaque by passivation, nerve dissection of the central nervous system, incompetent valves, pulmonary embolism, narrowing of a body passageway, and combinations thereof, said expandable medical device including a body having an unexpanded and expanded cross-section area and a biological agent coated or impregnated on an other surface of said body, majority of said body is formed of a biodegradable polymer system designed to degrade when exposed to fluids in the body passageway so that at least a portion of said body degrades over time and removes itself from a treatment site in said body passageway, a portion of an outer surface of said medical device including a plurality of microstructures that extend upwardly from and above said outer surface of said body, said plurality of microstructures at least partially formed of said biological agent, said plurality of microstructures having a shape and size that is designed to penetrate into said body passageway at the treatment site when said body is expanded to said expanded cross-sectional area and to deliver said biological agent in said penetrated region of said body passageway, said plurality of microstructures having a height of less than 1000 microns. 2. The expandable medical device as defined in claim 1, wherein said body is in the form of a stent. 3. The expandable medical device as defined in claim 2, wherein said body is formed of about 100 percent biodegradable material. 4. The expandable medical device as defined in claim 3, wherein said outer surface of said body including a body coating, said plurality of microstructures extending upwardly from said body coating, said body coating including biodegradable polymer, biological agent, and combinations thereof, said body coating having a different composition from said biodegradable polymer system of said body, said body coating having a thickness of at least about 0.01 μm to less than about less than about 150 μm. 5. The expandable medical device as defined in claim 1, wherein said body is formed of about 100 percent biodegradable material. 6. The expandable medical device as defined in claim 1, wherein said outer surface of said body including a body coating, said plurality of microstructures extending upwardly from said body coating, said body coating including biodegradable polymer, biological agent, and combinations thereof, said body coating having a different composition from said biodegradable polymer system of said body, said body coating having a thickness of at least about 0.01 μm to less than about less than about 150 μm. 7. The expandable medical device as defined in claim 6, including a protective outer polymer coating on said body coating, said protective outer polymer coating including a) one or more polymers selected from the group consisting of parylene, PLGA, PEVA, PBMA, PLA, POE, PGA, PLLA, PAA, PEG and chitosan, b) one or more derivatives of polymers selected from the group consisting of parylene, PLGA, PEVA, PBMA, PLA, POE, PGA, PLLA, PAA, PEG and chitosan, or c) a combination of a) and b). 8. The expandable medical device as defined in claim 6, wherein said protective outer polymer coating controls a rate of degradation of said biodegradable polymer on said body. 9. The expandable medical device as defined in claim 1, including a protective outer polymer coating on said plurality of microstructures, said protective outer polymer coating including a biodegradable polymer, said protective coating designed to inhibit or prevent damage to said plurality of microstructures as said body is inserted into said body passageway and to said treatment site, said protective outer polymer coating having a thickness of less than about 300 μm. 10. The expandable medical device as defined in claim 4, including a protective outer polymer coating on said plurality of microstructures, said protective outer polymer coating including a biodegradable polymer, said protective coating designed to inhibit or prevent damage to said plurality of microstructures as said body is inserted into said body passageway and to said treatment site, said protective outer polymer coating having a thickness of less than about 300 μm. 11. The expandable medical device as defined in claim 10, including a protective outer polymer coating on said body coating, said protective outer polymer coating including a) one or more polymers selected from the group consisting of parylene, PLGA, PEVA, PBMA, PLA, POE, PGA, PLLA, PAA, PEG and chitosan, b) one or more derivatives of polymers selected from the group consisting of parylene, PLGA, PEVA, PBMA, PLA, POE, PGA, PLLA, PAA, PEG and chitosan, or c) a combination of a) and b). 12. The expandable medical device as defined in claim 11, wherein said protective outer polymer coating controls a rate of degradation of said biodegradable polymer on said body. 13. The expandable medical device as defined in claim 12, wherein said agent ranging from about 0.01-100 ug per mm2, said agent at least about 0.01 weight percent of the device, and combinations thereof. 14. The expandable medical device as defined in claim 13, wherein said biological agent is used to promote the growth of an integral endothelial layer. 15. The expandable medical device as defined in claim 14, wherein said biological agent includes a) one or more agents selected from the group consisting of trapidil, taxol, cytochalasin, paclitaxel, rapamycin, and GM-CSF, b) one or more agents selected from the group consisting of trapidil derivative, taxol derivative, cytochalasin derivative, paclitaxel derivative, rapamycin derivative, and GM-CSF derivative, or c) a combination of a) and b). 16. The expandable medical device as defined in claim 15, wherein said body includes a plurality of high strain regions when said body is expanded from said unexpanded cross-sectional area and to said expanded cross-sectional area, a plurality of said high strain regions formed of biodegradable material so that such high strain regions degrade at a faster rate as compared to non-high strain regions on said body. 17. The expandable medical device as defined in claim 16, wherein said body contacts a balloon, a sheath, or combination thereof when inserted in to said body passageway, a plurality of said microstructures deigned to increase retention of said body to said balloon, said sheath, or combinations thereof. 18. The expandable medical device as defined in claim 17, wherein said biological agent is incorporated into said body. 19. The expandable medical device defined in claim 1, wherein said agent ranging from about 0.01-100 ug per mm2, said agent at least about 0.01 weight percent of the device, and combinations thereof. 20. The expandable medical device as defined in claim 1, wherein said biological agent is used to promote the growth of an integral endothelial layer. 21. The expandable medical device as defined in claim 1, wherein said biological agent includes a) one or more agents selected from the group consisting of trapidil, taxol, cytochalasin, paclitaxel, rapamycin, and GM-CSF, b) one or more agents selected from the group consisting of trapidil derivative, taxol derivative, cytochalasin derivative, paclitaxel derivative, rapamycin derivative, and GM-CSF derivative, or c) a combination of a) and b). 22. The expandable medical device as defined in claim 1, wherein said body includes a plurality of high strain regions when said body is expanded from said unexpanded cross-sectional area and to said expanded cross-sectional area, a plurality of said high strain regions formed of biodegradable material so that such high strain regions degrade at a faster rate as compared to non-high strain regions on said body. 23. The expandable medical device as defined in claim 1, wherein said body contacts a balloon, a sheath, or combination thereof when inserted in to said body passageway, a plurality of said microstructures deigned to increase retention of said body to said balloon, said sheath, or combinations thereof. 24. The expandable medical device as defined in claim 1, wherein said biological agent is incorporated into said body. 25. The expandable medical device as defined in claim 1, wherein said plurality of biodegradable microstructures extend upwardly from said body having a height of at least about 0.01 μm to less than about 300 μm.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (181)
Ivn Bla (Akron OH) Kennedy Joseph P. (Akron OH) Mackey Paul W. (Akron OH), Amphiphilic networks.
Hirt Thomas ; Lohmann Dieter,CHX ; Hopken Jens,DEX ; Liu Qin, Amphiphilic, segmented copolymer of controlled morphology and ophthalmic devices including contact lenses made therefrom.
Iyer, Sriram S.; Kipshidze, Nicholas N.; Nikolaychik, Victor V., Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts.
Buscemi Paul J. (Long Lake MN) Stejskal Elizabeth A. (St. Paul MN) Palme ; II Donald F. (Dayton MN) Wang Lixiao (St. Paul MN), Biodegradable drug delivery vascular stent.
Fearnot Neal E. (West Lafayette IN) Kozma Thomas G. (West Lafayette IN) Ragheb Anthony O. (West Lafayette IN) Voorhees William D. (West Lafayette IN), Coated implantable medical device.
Ragheb, Anthony O.; Bates, Brian L.; Fearnot, Neal E.; Kozma, Thomas G.; Voorhees, III, William D.; Gershlick, Anthony H., Coated implantable medical device.
Eury Robert P. (Cupertino CA) Garguilo Darlene (Fremont CA) Villareal Plaridel (San Jose CA), Drug loaded polymeric material and method of manufacture.
Tang Reginald T. (Somerset NJ) Mares Frank (Morris NJ) Boyle ; Jr. William J. (Morris NJ) Chiu Tin-Ho (Essex NJ) Patel Kundan M. (Morris NJ), Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lact.
Hermes Matthew E. (Easton CT) Muth Ross R. (Brookfield CT), Method for improving the storage stability of a polymeric article susceptible to hydrolytic degradation and resulting ar.
Kinsella James L. (Baltimore MD) Sollott Steven J. (Baltimore MD), Method of treating atherosclerosis or restenosis using microtubule stabilizing agent.
Askanazi Jeffrey (Haworth NJ) Katz David P. (Dobbs Ferry NY) Manner Tuula (Turku FIX), Methods and compositions for treating acute or chronic pain and drug addiction.
Singer Dinah S. (Chevy Chase MD) Kohn Leonard (Bethesda MD) Mozes Edna (Rehovot IL) Saji Motoyasu (Rockville MD) Weissman Jocelyn (Silver Spring MD) Napolitano Giorgio (Rockville MD) Ledley Fred D. (, Methods for assessing the ability of a candidate drug to suppress MHC class I expression.
Garvey, David S.; Letts, L. Gordon; Lin, Chia-En; Richardson, Stewart K.; Wang, Tiansheng, Nitrosated and nitrosylated taxanes, compositions and methods of use.
Swan Dale G. (St. Louis Park MN) Josephson Mark W. (Richfield MN) Swanson Melvin J. (Carver MN), Preparation of crosslinked matrices containing covalently immobilized chemical species and unbound releasable chemical s.
Williams Simon F. ; Martin David P. ; Gerngross Tillman ; Horowitz Daniel M., Removing endotoxin with an oxdizing agent from polyhydroxyalkanoates produced by fermentation.
Bates, Brian L.; Fearnot, Neal E.; Kozma, Thomas G.; Osborne, Thomas A.; Ragheb, Anthony O.; Roberts, Joseph W.; Voorhees, III, William D., Silver implantable medical device.
Ragheb Anthony O. ; Bates Brian L. ; Fearnot Neal E. ; Osborne Thomas A. ; Kozma Thomas G. ; Roberts Joseph W. ; Voorhees ; III William D., Silver implantable medical device.
Scott Neal A. (Atlanta GA) Hanson Stephen R. (Stone Mountain GA) King ; III Spencer B. (Atlanta GA) Harker Laurence A. (Atlanta GA), Stent sheath for local drug delivery.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GB2 ; Metcalfe James C.,GB2 ; Weissberg Peter L.,GB2 ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.